“…Aiming at these desired pharmacodynamic profiles, diimines, tetradentate ligands and substituted derivatives as ligands are currently attractive in the discovery of metal-based drugs for different cancers [ 25 , 26 ]. These coordinated or transition metal complexes have been found to be potent as cell cycle inhibitors [ 27 , 28 , 29 ], DNA topoisomerase inhibitors [ 30 , 31 ], pro- and anti-apoptotic protein modulators (p53, Bax and Bcl-2) [ 32 , 33 , 34 ], etc. Particularly, these metal complexes bring about cancer cell death through inhibition of DNA synthesis [ 14 , 26 , 28 , 35 ], alteration of mitochondrial membrane potential and/or suppression of inhibitors of apoptosis [ 26 , 36 , 37 ].…”